Prevalence of multidrug-resistant tuberculosis cases among HIV-positive and HIV-negative patients eligible for retreatment regimen in Togo using GeneXpert MTB/RIF
Drug-resistant tuberculosis (TB) is emerging as an important health problem in Togo. From sputum of previously treated TB patients, multidrug-resistant (MDR) TB was diagnosed in 24% (10/42) patients via GeneXpert MTB/RIF compared to 25% (6/24) patients via conventional drug susceptibility testing (B...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2015-11-01
|
| Series: | New Microbes and New Infections |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2052297515000669 |
| _version_ | 1818031982982987776 |
|---|---|
| author | A.Y. Dagnra K.D. Mlaga K. Adjoh E. Kadanga K. Disse T. Adekambi |
| author_facet | A.Y. Dagnra K.D. Mlaga K. Adjoh E. Kadanga K. Disse T. Adekambi |
| author_sort | A.Y. Dagnra |
| collection | DOAJ |
| description | Drug-resistant tuberculosis (TB) is emerging as an important health problem in Togo. From sputum of previously treated TB patients, multidrug-resistant (MDR) TB was diagnosed in 24% (10/42) patients via GeneXpert MTB/RIF compared to 25% (6/24) patients via conventional drug susceptibility testing (BACTEC MGIT 960 system). The agreement between these two methods to detect MDR-TB is excellent. However, GeneXpert MTB/RIF offers the advantage of rapidly detecting Mycobacterium tuberculosis complex in sputum samples in instances where the cultures are negative (33%, 14/42) or contaminated (9.5%, 4/42). GeneXpert MTB/RIF permitted us to estimate the prevalence of MDR-TB in previously treated TB patients and to improve TB diagnostics among HIV-positive and -negative patients in Togo, where culturing M. tuberculosis complex from sputum samples is challenging. |
| first_indexed | 2024-12-10T06:00:08Z |
| format | Article |
| id | doaj.art-fd221fc6f41946acbea9fcfb47627a1d |
| institution | Directory Open Access Journal |
| issn | 2052-2975 |
| language | English |
| last_indexed | 2024-12-10T06:00:08Z |
| publishDate | 2015-11-01 |
| publisher | Elsevier |
| record_format | Article |
| series | New Microbes and New Infections |
| spelling | doaj.art-fd221fc6f41946acbea9fcfb47627a1d2022-12-22T01:59:51ZengElsevierNew Microbes and New Infections2052-29752015-11-018C242710.1016/j.nmni.2015.09.001Prevalence of multidrug-resistant tuberculosis cases among HIV-positive and HIV-negative patients eligible for retreatment regimen in Togo using GeneXpert MTB/RIFA.Y. Dagnra0K.D. Mlaga1K. Adjoh2E. Kadanga3K. Disse4T. Adekambi5Université de Lomé, Laboratoire National de Référence des Mycobactéries, and Programme National de Lutte Contre la Tuberculose, Lomé, TogoMedical Research Council Unit, Banjul, GambiaService de Pneumophysiologie, CHU Sylvanus Olympio, Lomé, TogoUniversité de Lomé, Laboratoire National de Référence des Mycobactéries, and Programme National de Lutte Contre la Tuberculose, Lomé, TogoService de Pneumophysiologie, CHU Sylvanus Olympio, Lomé, TogoEmory Vaccine Center, Emory University School of Medicine, Atlanta, GA, USADrug-resistant tuberculosis (TB) is emerging as an important health problem in Togo. From sputum of previously treated TB patients, multidrug-resistant (MDR) TB was diagnosed in 24% (10/42) patients via GeneXpert MTB/RIF compared to 25% (6/24) patients via conventional drug susceptibility testing (BACTEC MGIT 960 system). The agreement between these two methods to detect MDR-TB is excellent. However, GeneXpert MTB/RIF offers the advantage of rapidly detecting Mycobacterium tuberculosis complex in sputum samples in instances where the cultures are negative (33%, 14/42) or contaminated (9.5%, 4/42). GeneXpert MTB/RIF permitted us to estimate the prevalence of MDR-TB in previously treated TB patients and to improve TB diagnostics among HIV-positive and -negative patients in Togo, where culturing M. tuberculosis complex from sputum samples is challenging.http://www.sciencedirect.com/science/article/pii/S2052297515000669 |
| spellingShingle | A.Y. Dagnra K.D. Mlaga K. Adjoh E. Kadanga K. Disse T. Adekambi Prevalence of multidrug-resistant tuberculosis cases among HIV-positive and HIV-negative patients eligible for retreatment regimen in Togo using GeneXpert MTB/RIF New Microbes and New Infections |
| title | Prevalence of multidrug-resistant tuberculosis cases among HIV-positive and HIV-negative patients eligible for retreatment regimen in Togo using GeneXpert MTB/RIF |
| title_full | Prevalence of multidrug-resistant tuberculosis cases among HIV-positive and HIV-negative patients eligible for retreatment regimen in Togo using GeneXpert MTB/RIF |
| title_fullStr | Prevalence of multidrug-resistant tuberculosis cases among HIV-positive and HIV-negative patients eligible for retreatment regimen in Togo using GeneXpert MTB/RIF |
| title_full_unstemmed | Prevalence of multidrug-resistant tuberculosis cases among HIV-positive and HIV-negative patients eligible for retreatment regimen in Togo using GeneXpert MTB/RIF |
| title_short | Prevalence of multidrug-resistant tuberculosis cases among HIV-positive and HIV-negative patients eligible for retreatment regimen in Togo using GeneXpert MTB/RIF |
| title_sort | prevalence of multidrug resistant tuberculosis cases among hiv positive and hiv negative patients eligible for retreatment regimen in togo using genexpert mtb rif |
| url | http://www.sciencedirect.com/science/article/pii/S2052297515000669 |
| work_keys_str_mv | AT aydagnra prevalenceofmultidrugresistanttuberculosiscasesamonghivpositiveandhivnegativepatientseligibleforretreatmentregimenintogousinggenexpertmtbrif AT kdmlaga prevalenceofmultidrugresistanttuberculosiscasesamonghivpositiveandhivnegativepatientseligibleforretreatmentregimenintogousinggenexpertmtbrif AT kadjoh prevalenceofmultidrugresistanttuberculosiscasesamonghivpositiveandhivnegativepatientseligibleforretreatmentregimenintogousinggenexpertmtbrif AT ekadanga prevalenceofmultidrugresistanttuberculosiscasesamonghivpositiveandhivnegativepatientseligibleforretreatmentregimenintogousinggenexpertmtbrif AT kdisse prevalenceofmultidrugresistanttuberculosiscasesamonghivpositiveandhivnegativepatientseligibleforretreatmentregimenintogousinggenexpertmtbrif AT tadekambi prevalenceofmultidrugresistanttuberculosiscasesamonghivpositiveandhivnegativepatientseligibleforretreatmentregimenintogousinggenexpertmtbrif |